NASDAQ:ANCN - Nasdaq -
4.71
+0.24 (+5.37%)
The current stock price of ANCN is 4.71 null. In the past month the price decreased by -3.68%. In the past year, price increased by 640.57%.
Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company. It focuses on the discovery and development of novel therapies to treat cancer. The company's product candidate, inodiftagene vixteplasmid, is in development as a treatment for non-muscle-invasive bladder cancer. It operates primarily in Cambridge, MA and Jerusalem, Israel. Anchiano Therapeutics Ltd. is based in CAMBRIDGE.
Anchiano Therapeutics Ltd ADR
ONE KENDALL SQUARE BUILDING 400 SUITE 14-105
JERUSALEM L3 9777401
CEO: Dr. Frank Haluska
Phone: 857-259-4622
The current stock price of ANCN is 4.71 null. The price increased by 5.37% in the last trading session.
The exchange symbol of Anchiano Therapeutics Ltd ADR is ANCN and it is listed on the Nasdaq exchange.
ANCN stock is listed on the Nasdaq exchange.
Anchiano Therapeutics Ltd ADR (ANCN) has a market capitalization of 34.95M null. This makes ANCN a Nano Cap stock.
Anchiano Therapeutics Ltd ADR (ANCN) has a support level at 3.08 and a resistance level at 4.72. Check the full technical report for a detailed analysis of ANCN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ANCN does not pay a dividend.
Anchiano Therapeutics Ltd ADR (ANCN) will report earnings on 2022-03-08, before the market open.
The PE ratio for Anchiano Therapeutics Ltd ADR (ANCN) is 6.04. This is based on the reported non-GAAP earnings per share of 0.78 and the current share price of 4.71 null. Check the full fundamental report for a full analysis of the valuation metrics for ANCN.
ChartMill assigns a technical rating of 9 / 10 to ANCN. When comparing the yearly performance of all stocks, ANCN is one of the better performing stocks in the market, outperforming 98.01% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to ANCN. ANCN may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ANCN reported a non-GAAP Earnings per Share(EPS) of 0.78. The EPS increased by 34.1% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -187.88% | ||
ROE | N/A | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 60% to ANCN. The Buy consensus is the average rating of analysts ratings from 1 analysts.